Identification of novel IGRP epitopes targeted in type 1 diabetes patients

Irene Jarchum, Lynn Nichol, Massimo Trucco, Pere Santamaria, Teresa P. DiLorenzo

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

CD8+ T cells play an important role in the development of type 1 diabetes (T1D) in NOD mice and humans. IGRP (islet-specific glucose-6-phosphatase catalytic subunit-related protein) has emerged in recent years as a major antigen in NOD mice. Therefore, we aimed to determine if IGRP is an antigen in T1D patients and to identify the HLA-A2-restricted IGRP epitopes targeted. Using IFN-γ ELISPOT assay, we tested PBMC from recent-onset pediatric T1D patients and healthy controls for reactivity to four IGRP peptides directly ex vivo. Importantly, 65% of patients and 0% of controls were positive for at least one IGRP peptide. Two of these have not been reported previously. These data provide evidence that IGRP is a CD8+ T cell antigen in humans, contributing to the understanding of the underlying disease process as well as to future directions for diagnosis and monitoring disease progression in T1D patients.

Original languageEnglish (US)
Pages (from-to)359-365
Number of pages7
JournalClinical Immunology
Volume127
Issue number3
DOIs
StatePublished - Jun 2008

Fingerprint

Type 1 Diabetes Mellitus
Epitopes
Inbred NOD Mouse
T-Lymphocytes
HLA-A2 Antigen
Enzyme-Linked Immunospot Assay
Antigens
Glucose-6-Phosphatase
Peptides
Viral Tumor Antigens
Disease Progression
Catalytic Domain
Pediatrics
Proteins

Keywords

  • Antigens
  • Autoimmunity
  • Diabetes
  • Human
  • IGRP
  • T cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Identification of novel IGRP epitopes targeted in type 1 diabetes patients. / Jarchum, Irene; Nichol, Lynn; Trucco, Massimo; Santamaria, Pere; DiLorenzo, Teresa P.

In: Clinical Immunology, Vol. 127, No. 3, 06.2008, p. 359-365.

Research output: Contribution to journalArticle

Jarchum, Irene ; Nichol, Lynn ; Trucco, Massimo ; Santamaria, Pere ; DiLorenzo, Teresa P. / Identification of novel IGRP epitopes targeted in type 1 diabetes patients. In: Clinical Immunology. 2008 ; Vol. 127, No. 3. pp. 359-365.
@article{7e9b199d1a47420ab4d8c1a5fe8a3dc1,
title = "Identification of novel IGRP epitopes targeted in type 1 diabetes patients",
abstract = "CD8+ T cells play an important role in the development of type 1 diabetes (T1D) in NOD mice and humans. IGRP (islet-specific glucose-6-phosphatase catalytic subunit-related protein) has emerged in recent years as a major antigen in NOD mice. Therefore, we aimed to determine if IGRP is an antigen in T1D patients and to identify the HLA-A2-restricted IGRP epitopes targeted. Using IFN-γ ELISPOT assay, we tested PBMC from recent-onset pediatric T1D patients and healthy controls for reactivity to four IGRP peptides directly ex vivo. Importantly, 65{\%} of patients and 0{\%} of controls were positive for at least one IGRP peptide. Two of these have not been reported previously. These data provide evidence that IGRP is a CD8+ T cell antigen in humans, contributing to the understanding of the underlying disease process as well as to future directions for diagnosis and monitoring disease progression in T1D patients.",
keywords = "Antigens, Autoimmunity, Diabetes, Human, IGRP, T cells",
author = "Irene Jarchum and Lynn Nichol and Massimo Trucco and Pere Santamaria and DiLorenzo, {Teresa P.}",
year = "2008",
month = "6",
doi = "10.1016/j.clim.2008.01.015",
language = "English (US)",
volume = "127",
pages = "359--365",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Identification of novel IGRP epitopes targeted in type 1 diabetes patients

AU - Jarchum, Irene

AU - Nichol, Lynn

AU - Trucco, Massimo

AU - Santamaria, Pere

AU - DiLorenzo, Teresa P.

PY - 2008/6

Y1 - 2008/6

N2 - CD8+ T cells play an important role in the development of type 1 diabetes (T1D) in NOD mice and humans. IGRP (islet-specific glucose-6-phosphatase catalytic subunit-related protein) has emerged in recent years as a major antigen in NOD mice. Therefore, we aimed to determine if IGRP is an antigen in T1D patients and to identify the HLA-A2-restricted IGRP epitopes targeted. Using IFN-γ ELISPOT assay, we tested PBMC from recent-onset pediatric T1D patients and healthy controls for reactivity to four IGRP peptides directly ex vivo. Importantly, 65% of patients and 0% of controls were positive for at least one IGRP peptide. Two of these have not been reported previously. These data provide evidence that IGRP is a CD8+ T cell antigen in humans, contributing to the understanding of the underlying disease process as well as to future directions for diagnosis and monitoring disease progression in T1D patients.

AB - CD8+ T cells play an important role in the development of type 1 diabetes (T1D) in NOD mice and humans. IGRP (islet-specific glucose-6-phosphatase catalytic subunit-related protein) has emerged in recent years as a major antigen in NOD mice. Therefore, we aimed to determine if IGRP is an antigen in T1D patients and to identify the HLA-A2-restricted IGRP epitopes targeted. Using IFN-γ ELISPOT assay, we tested PBMC from recent-onset pediatric T1D patients and healthy controls for reactivity to four IGRP peptides directly ex vivo. Importantly, 65% of patients and 0% of controls were positive for at least one IGRP peptide. Two of these have not been reported previously. These data provide evidence that IGRP is a CD8+ T cell antigen in humans, contributing to the understanding of the underlying disease process as well as to future directions for diagnosis and monitoring disease progression in T1D patients.

KW - Antigens

KW - Autoimmunity

KW - Diabetes

KW - Human

KW - IGRP

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=45249117656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45249117656&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2008.01.015

DO - 10.1016/j.clim.2008.01.015

M3 - Article

C2 - 18358785

AN - SCOPUS:45249117656

VL - 127

SP - 359

EP - 365

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -